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Snakebite envenoming represents an important public health problem in many 
tropical and subtropical countries, and has been aptly described as a disease of poverty. 
Most snakebite envenomations occur in low-income regions of Africa, Asia, and Central 
and South America. In sub-Saharan Africa, each year 1.000.000 bites cause 500.000 
envenomations and 3.500-32.000 fatalities. However, despite the magnitude of its 
effects, the snakebite pathology has not received the attention it deserves, and has been 
categorized by the WHO as a neglected tropical disease. The severe shortage of 
commercial antivenoms in Africa provided an opportunity for unscrupulous marketing 
of inappropriate antivenoms that have proved clinically disastrous. This sad situation has 
prompted manufacturers in other parts of the world to provide antivenoms for Africa. 
Thus, in addition to laboratories traditionally producing antivenoms for Africa, such as 
EgyVac (Egypt), Sanofi-Pasteur (France) and South African Vaccine Producers (South 
Africa), in recent years other manufacturers, such as MicroPharm Ltd. (UK), Instituto 
Bioclon (Mexico), Instituto Butantan (Brazil), and Instituto Clodomiro Picado (Costa 
Rica), have developed new antivenoms against the most medically relevant African 
snake venoms. We have applied in vivo neutralization assays and antivenomics to assess 
the pre-clinical neutralization efficacy and the immunological cross-reactivity of 
EchiTAb-Plus-ICP
®
 toward seven species of sub-Saharan snakes, e.g. E. ocellatus 
(Nigeria), E. leucogaster (Mali), E pyramidum leakey (Kenya), Bitis arietans arietans 
(from Ghana and Nigeria), B. gabonica gabonica, B. rhinoceros, and B. nasicornis 
(undisclosed origin). The antivenom showed high degree of cross-reactivity against all 
venoms tested, although a small number of venom proteins (primarily PLA2s, 
disintegrins, and Kunitz-type inhibitor) were only partially immunodepleted from the 
venoms.  Now, we have investigated the toxin composition of venoms from African 
spitting cobras, and have assessed the ability of the EchiTAb-Plus-ICP
®
 antivenom to 
neutralize their toxicological activities by combination of standard laboratory tests in 
mice and antivenomics. 
